Results 211 to 220 of about 42,721 (245)
Some of the next articles are maybe not open access.
Journal of Investigative Medicine
Three biomarkers for immune checkpoint inhibitors—mismatch repair (MMR)/microsatellite instability, tumor mutation burden, and PD-L1 ligand expression—are currently approved for utilization in therapeutic decisions. The adoption of these biomarkers has gained ground gradually following demonstrated clinical utility.
Hailey, O'Grady +3 more
openaire +2 more sources
Three biomarkers for immune checkpoint inhibitors—mismatch repair (MMR)/microsatellite instability, tumor mutation burden, and PD-L1 ligand expression—are currently approved for utilization in therapeutic decisions. The adoption of these biomarkers has gained ground gradually following demonstrated clinical utility.
Hailey, O'Grady +3 more
openaire +2 more sources
[Methylation of mismatch repair gene (MMR) in primary hepatocellular carcinoma].
Zhonghua bing li xue za zhi = Chinese journal of pathology, 2006To assess the role of methylated mismatch repair (MMR) genes (hMLH1, hMSH2 and hMSH3) in the carcinogenesis and progression of hepatocellular carcinoma (HCC).Samples of 38 cases of HCC along with their corresponding noncancerous tissues, 2 samples of donated normal tissue and 6 cell lines were collected and subject to the methylation-specific PCR (MSP)
Cui-juan, Zhang +6 more
openaire +1 more source
Clinical characterization of DNA mismatch repair deficiency (MMR-D) in endometrial cancer (EC).
Journal of Clinical Oncology, 20161522Background: MMR-D, characterized by loss of protein expression of MMR protein(s) (MLH1, MSH2, MSH6, PMS2) by immunohistochemistry (IHC) occurs in 20-25% of ECs & serves as a screening test for ...
Karen Anne Cadoo +15 more
openaire +1 more source
Impact of mismatch repair (MMR) testing on colorectal cancer (CRC) oncology clinical practice.
Journal of Clinical Oncology, 2012603 Background: MMR deficiency (dMMR) has been reported in 15% of CRC, but with a lower frequency in advanced disease. Most cases are due to sporadic MLH1 promoter hypermethylation (often with BRAF mutations), with a minority reflecting germline mutations in MLH1, MSH2, PMS2, or MSH6 (Lynch Syndrome [LS]).
Madeleine Hewish +15 more
openaire +1 more source
Russian Journal of Genetics, 2008
Total repair capability is a widely used phenotypic marker of predisposition to cancer. Evaluation of this parameter implies using a challenge mutagen in an in vitro system to unmask latent genetic instability and repair insufficiency in the target cells.
V A, Tronov +2 more
openaire +2 more sources
Total repair capability is a widely used phenotypic marker of predisposition to cancer. Evaluation of this parameter implies using a challenge mutagen in an in vitro system to unmask latent genetic instability and repair insufficiency in the target cells.
V A, Tronov +2 more
openaire +2 more sources
Cancer Research, 2015
Abstract Background: Germline mutations of BRCA1, BRCA2, MLH1, MSH2, and MSH6 are known to increase risk of pancreatic cancer. However, the prevalence of pathogenic germline mutations of these genes among pancreatic cancer patients is unknown.
Iris Selander +8 more
openaire +1 more source
Abstract Background: Germline mutations of BRCA1, BRCA2, MLH1, MSH2, and MSH6 are known to increase risk of pancreatic cancer. However, the prevalence of pathogenic germline mutations of these genes among pancreatic cancer patients is unknown.
Iris Selander +8 more
openaire +1 more source
Current Pharmacogenomics and Personalized Medicine
Introduction: This study evaluates the efficacy of immunotherapy with PD-1 inhibitors, such as pembrolizumab, in advanced cancers associated with defects in the DNA mismatch repair (dMMR) system and high microsatellite instability (MSI-H). Method:
Andre Torres Garcia +4 more
openaire +1 more source
Introduction: This study evaluates the efficacy of immunotherapy with PD-1 inhibitors, such as pembrolizumab, in advanced cancers associated with defects in the DNA mismatch repair (dMMR) system and high microsatellite instability (MSI-H). Method:
Andre Torres Garcia +4 more
openaire +1 more source
Interactive regulation of human mismatch repair(MMR)system components in MMR deficient cells
Gastroenterology, 2000Dong K. Chang +4 more
openaire +1 more source
Stoichiometry of the DNA mismatch repair (MMR) proteins in MMR-proficient cell lines
Gastroenterology, 2000Dong K. Chang +4 more
openaire +1 more source
Diseases of Mismatch Repair (MMR)
Reactome - a curated knowledgebase of biological pathways, 2017openaire +1 more source